Design, Synthesis, and Preliminary Pharmacological Evaluation of 1,4-Diazabicyclo[4.3.0]nonan-9-ones as a New Class of Highly Potent Nootropic Agents
- 18 April 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (10) , 1969-1974
- https://doi.org/10.1021/jm991170t
Abstract
Several 4-substituted 1,4-diazabicyclo[4.3.0]nonan-9-ones have been synthesized and tested in vivo on mouse passive avoidance test, to evaluate their nootropic activity. The results show that they represent a new class of nootropic drugs with a pharmacological profile very similar to that of piracetam, showing much higher potency with respect to the reference. Among the compounds studied, 7 (DM 232) shows outstanding potency, being active at the dose of 0.001 mg kg-1 sc.Keywords
This publication has 12 references indexed in Scilit:
- Modulation of the neuronal nicotinic acetylcholine receptor-channel by the nootropic drug nefiracetamBrain Research, 1999
- Cognitive Enhancement Therapy for Alzheimerʼs DiseaseDrugs, 1997
- In search of the mechanism of action of the nootropics: New insights and potential clinical implicationsLife Sciences, 1994
- Piracetam and other structurally related nootropicsBrain Research Reviews, 1994
- Ameliorating effects of nefiracetam (DM-9384) on brain dysfunctionDrugs of Today, 1994
- Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancersJournal of Medicinal Chemistry, 1993
- Long‐term and high‐dose piracetam treatment of Alzheimer's diseaseNeurology, 1993
- How long does ‘memory consolidation’ take? New compounds can improve retention performance, even if administered up to 24 hours after the learning experienceBrain Research, 1991
- Synthesis and cognition-activating properties of some mono- and bicyclic lactam derivativesJournal of Medicinal Chemistry, 1988
- Psychostimulants, Analeptics, Nootropics: An Attempt to Differentiate and Assess Drugs Designed for the Treatment of Impaired Brain FunctionsPharmacopsychiatry, 1988